Treatment for Herpes Zoster Pain Using Dexmedetomidine and High Voltage Therapy
The Clinical Efficacy Analysis of Long-Duration High-Voltage Pulsed Radiofrequency Combined With Dexmedetomidine Nasal Spray in the Treatment of Herpes Zoster-Associated Neuropathic Pain
This study is testing whether a nasal spray with dexmedetomidine, used alongside high-voltage therapy, can help people with painful herpes zoster feel better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 92 (estimated) |
| Ages | 40 Years to 85 Years |
| Sex | All |
| Sponsor | Zunyi Medical College Academic / other |
| Locations | 1 site (Zunyi, Guizhou) |
| Trial ID | NCT06978192 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of dexmedetomidine nasal spray combined with long-term high-voltage pulsed radiofrequency therapy for treating pain associated with herpes zoster. Participants will be randomly assigned to either an experimental group receiving the nasal spray or a control group receiving standard treatment with high-voltage therapy. The study aims to assess pain relief and the impact on daily life for patients suffering from recurrent herpes zoster pain. Heart rate and blood pressure will be monitored throughout the treatment process.
Who should consider this trial
Good fit: Ideal candidates are patients aged 40-85 with recurrent herpes zoster pain who have not responded to conventional drug treatments.
Not a fit: Patients with severe organ failure, systemic infections, or contraindications to the proposed therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly alleviate pain for patients suffering from herpes zoster, improving their quality of life.
How similar studies have performed: While this approach combines established treatments, the specific combination of dexmedetomidine and high-voltage therapy is novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with adverse reactions that are not effective in conventional drug treatment and cannot tolerate drugs * The pain is located in the corresponding innervated are * The pain affects the patient's daily life or work * Diagnostic nerve block is effective and pain limited * Recurrent herpes zoster pain * Patients with shingle-related pain aged 40-85 years Exclusion Criteria: * Infection at the puncture site, systemic infection that may spread, and malignant tumors near the puncture * There are contraindications in minimally invasive interventional therapy such as coagulation function and platelet dysfunction * Allergies to local anesthetics and inhalants * Heart, lung, liver, kidney and other important organ failure, can not tolerate surgery * Severe endocrine system diseases or long-term use of hormone or immunosuppressive therapy * Patients with cardiac pacemakers, pregnant or lactating women * Patients with cognitive dysfunction or poor coordination * Patients who have been treated with electrical stimulation or PRF
Where this trial is running
Zunyi, Guizhou
- Affiliated Hospital of Zunyi Medical University — Zunyi, Guizhou, China (Recruiting)
Study contacts
- Principal investigator: Deng — Fenghui
- Study coordinator: Fenghui Deng
- Email: 254670750@qq.com
- Phone: +8615185817588
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.